Assessment identifies potential risks of drug-drug interactions in psychiatric inpatients, highlighting the role of cytochrome P450 enzymes.
Polypharmacy increases the risk of drug–drug interactions (DDIs) among patients with psychiatric disorders. Several psychiatric medications act as substrates, inhibitors, or inducers of cytochrome P450 (CYP), necessitating careful evaluation of CYP-mediated DDIs before administration. This study aimed to evaluate the potential risk of CYP-mediated DDIs among psychiatric inpatients.
No takes yet. Share an insight, caveat, or question.
Imai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: